Ascendia Pharmaceutical Solutions (formerly Ascendia Pharmaceuticals) is a leading specialty CDMO that makes the Impossible Possible through a comprehensive suite of pre-formulation, formulation development, cGMP manufacturing, and ICH stability services for a variety of dosage forms using its proprietary enabling nanotechnologies, including nano-emulsions, nanosuspensions, nanoparticles, lipid nanoparticles, and amorphous solid dispersion technology platforms. The company built its foundation of success on its customer-centric culture that cultivates its BEST philosophy (Brilliant technology, Excellent service, Superior quality, and Trust).
Its North Brunswick, NJ 60,000 square-foot facility has Class 10,000 (ISO 7) and Class 100 (ISO 5) cleanrooms, as well as Class 100,000 (ISO 8) manufacturing suites. It provides custom sterile and non-sterile enabling formulations, along with analytical methods for new chemical entities, complex dosage forms, and 505(B)(2) product development, as well as OTCs, veterinary drugs, and nutraceuticals.
Ascendia Pharmaceutical Solutions delivers sophisticated formulations to enhance bioavailability and solubility using four proprietary nanotechnologies – AmorSol®, EmulSol®, LipidSol™, and NanoSol®.